1. No category

State of the art
in the treatment
of hematological
malignancies
IV Pre Congress Meeting SEHH 2015
Chairman:
Dr. Miguel Ángel Sanz
Hospital Universitari i Politècnic La Fe. Valencia
Valencia,
21 October 2015
Palacio de Congresos de Valencia
st
Venue
Palacio de Congresos de Valencia
Avda. Cortes Valencianas, nº 60. Valencia
Organized by
Under the auspices of:
Thanks to an unrestricted grant of:
IV Pre Congress Meeting SEHH 2015
Valencia,
21st October 2015
Palacio de Congresos de Valencia
State of the art in the treatment
of hematological malignancies
MULTIPLE MYELOMA (MM) SESSION
NON-HODKING LYMPHOMA (NHL) SESSION (continue)
Follicular lymphoma (FL). Expert panel
Chair: Dr. Jesús F. San Miguel. Clínica Universidad de Navarra. Pamplona
Clinical decisions based on MM biology
11:00-11:15 h The extent of intra-clonal genetic diversity within the myeloma clone
Dr. Gareth Morgan. Myeloma Institute for Research and Therapy.
University of Arkansas for Medical Sciences. Arkansas (USA)
Dr. Franck Morschhauser. Centre Hospitalier Régional Universitaire de Lille. Lille (France)
15:55-16:05 h Panel discussion
Mantle cell lymphoma (MCL). Expert panel
and clinical behavior of MM. Optimizing MRD technique
Dr. Bruno Paiva. CIMA Lab Diagnostics.
Universidad de Navarra-Clínica Universidad de Navarra. Pamplona
11:30-11:45 h When I have to treat? SMM, biological relapse vs. CRAB
Dr. Joan Bladé. Hospital Clínic. Barcelona
15:40-15:55 h Relapsed/refractory status: old/new agents
Dr. Armando López Guillermo. Hospital Clínic. Barcelona
11:15-11:30 h Contributions of flow cytometry to biological knowledge
15:25-15:40 h Front-line therapy in advanced stage
16:05-16:20 h Optimizing strategies of ASCT in MCL
Dr. Alejandro Martín. Hospital Universitario de Salamanca
16:20-16:35 h New drugs in MCL
Dr. Steven Le Gouill. Centre Hospitalier Universitaire de Nantes. France
11:45-11:55 h Panel discussion
16:35-16:45 h Panel discussion
Current management and challenges in MM treatment
16:45 h Coffee break
11:55-12:10 h Optimizing the treatment of patients no SCT candidates and measuring
quality of life and its contribution to the value of novel agents
Dr. M.ª Victoria Mateos. Hospital Universitario de Salamanca
12:10-12:25 h Optimizing the treatment of patients SCT candidates
MYELODYSPLASIA (MDS) SESSION
Chair: Dr. Guillermo Sanz. Hospital Universitari i Politècnic La Fe. Valencia
in the era of the novel agents
Dr. Juan José Lahuerta. Hospital Universitario 12 de Octubre. Madrid
12:25-12:40 h Second and third generation of PI & IMiDs for relapsed
and refractory patients
Dr. Enrique M. Ocio. Hospital Universitario de Salamanca
12:40-12:55 h Immune checkpoint inhibitors in MM and other hematological malignancies
Dr. Paula Rodríguez. Clínica Universidad de Navarra. Pamplona
Dr. Juan Cruz Cigudosa. Centro Nacional de Investigaciones Oncológicas (CNIO). Madrid
17:30-17:45 h Insight in the future treatment options for MDS patients
Dr. Valeria Santini. University of Florence Medical School. Florence (Italy)
17:45-18:00 h Targeted treatment and cytogenetic abnormalities in MDS
Dr. David Valcárcel. Hospital Universitari Vall d’Hebron. Barcelona
12:55-13:05 h Panel discussion
17:15-17:30 h Citogenetic abnormalities
18:00-18:10 h Panel discussion
13:05 h Lunch
NON-HODKING LYMPHOMA (NHL) SESSION
ACUTE MYELOID LEUKEMIA (AML) SESSION
Chair: Dr. Miguel Ángel Sanz. Hospital Universitari i Politècnic La Fe. Valencia
Chair: Dr. M.ª Dolores Caballero. Hospital Universitario de Salamanca
Diffuse large B-cell lymphoma (DLBCL). Expert panel
14:45-15:00 h Lessons to be learned from molecular analysis
Dr. José Antonio Pérez Simón. Hospital Universitario Virgen del Rocío. Sevilla
Dr. Santiago Montes-Moreno. Hospital Universitario Marqués de Valdecilla. Santander
15:00-15:15 h Improving R-CHOP treatment
Dr. Annalisa Chiappella. Azienda Ospedaliero Universitaria Città della Salute
e della Scienza di Torino. Torino (Italy)
15:15-15:25 h Panel discussion
18:10-18:25 h Preclinical studies in AML
18:25-18:40 h Optimizing the management of AML patients (European perspective)
Dr. Lisa Pleyer. Salzburg Cancer Research Institute-Center for Clinical Cancer
and Immunology Trials. Salzburg (Austria)
18:40-18:55 h Optimizing the management of AML patients (Spanish perspective)
Dr. Pau Montesinos. Hospital Universitari i Politècnic La Fe. Valencia
18:55-19:05 h Panel discussion